Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2–negative advanced breast cancer: final overall survival results from SOLAR-1
André, F., Ciruelos, E.M., Juric, D., Loibl, S., Campone, M., Mayer, I.A., Rubovszky, G., Yamashita, T., Kaufman, B., Lu, Y.-S., Inoue, K., Pápai, Z., Takahashi, M., Ghaznawi, F., Mills, D., Kaper, M., Miller, M., Conte, P.F., Iwata, H., Rugo, H.S.
Published in Annals of oncology (01.02.2021)
Published in Annals of oncology (01.02.2021)
Get full text
Journal Article
Safety of everolimus plus exemestane in patients with hormone-receptor–positive, HER2–negative locally advanced or metastatic breast cancer progressing on prior non-steroidal aromatase inhibitors: primary results of a phase IIIb, open-label, single-arm, expanded-access multicenter trial (BALLET)
Jerusalem, G., Mariani, G., Ciruelos, E.M., Martin, M., Tjan-Heijnen, V.C.G., Neven, P., Gavila, J.G., Michelotti, A., Montemurro, F., Generali, D., Simoncini, E., Lang, I., Mardiak, J., Naume, B., Camozzi, M., Lorizzo, K., Bianchetti, S., Conte, P.
Published in Annals of oncology (01.09.2016)
Published in Annals of oncology (01.09.2016)
Get full text
Journal Article
P018 TROPION-Breast03: Datopotamab deruxtecan (Dato-DXd) ± durvalumab vs investigator’s choice of therapy (ICT) for triple-negative breast cancer (TNBC) with residual disease following neoadjuvant therapy
Bardia, A., Pusztai, L., Albain, K., Kalinsky, K., Hershman, D., Barlow, W., Tokunaga, E., Ciruelos, E.M., Loirat, D., Isaacs, C., Testa, L., Dry, H., Kozarski, R., Maxwell, M., Harbeck, N., Sharma, P.
Published in Breast (Edinburgh) (01.04.2023)
Published in Breast (Edinburgh) (01.04.2023)
Get full text
Journal Article
1850 Safety of everolimus plus exemestane in elderly patients with Hormone-Receptor-Positive (HR+), HER2- locally advanced or metastatic breast cancer progressing on prior non-steroidal aromatase inhibitors (NSAIs): BALLET (CRAD001YIC04)
Neven, P, Generali, D, Ciruelos, E.M, Lang, I, Gavila, J.G, Bighin, C, Borms, M, Conte, P, Montemurro, F, Sartori, D, Lee, T.V, Camozzi, M, Lorizzo, K, Ocak, O, Jerusalem, G
Published in European journal of cancer (1990) (01.09.2015)
Published in European journal of cancer (1990) (01.09.2015)
Get full text
Journal Article
Alpelisib (ALP) + fulvestrant (FUL) for advanced breast cancer (ABC): Results of the phase III SOLAR-1 trial
André, F., Ciruelos, E.M., Rubovszky, G., Campone, M., Loibl, S., Rugo, H.S., Iwata, H., Conte, P., Mayer, I.A., Kaufman, B., Yamashita, T., Lu, Y.-S., Inoue, K., Takahashi, M., Pápai, Z., Longin, A.-S., Mills, D., Wilke, C., Hirawat, S., Juric, D.
Published in Annals of oncology (01.10.2018)
Published in Annals of oncology (01.10.2018)
Get full text
Journal Article
Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study
Gianni, L., Huang, C.S., Egle, D., Bermejo, B., Zamagni, C., Thill, M., Anton, A., Zambelli, S., Bianchini, G., Russo, S., Ciruelos, E.M., Greil, R., Semiglazov, V., Colleoni, M., Kelly, C., Mariani, G., Del Mastro, L., Maffeis, I., Valagussa, P., Viale, G.
Published in Annals of oncology (01.05.2022)
Published in Annals of oncology (01.05.2022)
Get full text
Journal Article
Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer
Rugo, H.S., André, F., Yamashita, T., Cerda, H., Toledano, I., Stemmer, S.M., Jurado, J.C., Juric, D., Mayer, I., Ciruelos, E.M., Iwata, H., Conte, P., Campone, M., Wilke, C., Mills, D., Lteif, A., Miller, M., Gaudenzi, F., Loibl, S.
Published in Annals of oncology (01.08.2020)
Published in Annals of oncology (01.08.2020)
Get full text
Journal Article
3LBA SOLTI-0701: A double-blind, randomized phase 2b study evaluating the efficacy and safety of sorafenib (SOR) compared to placebo (PL) when administered in combination with capecitabine (CAP) in patients (pts) with locally advanced (adv) or metastatic (met) breast cancer (BC)
Baselga, J, Segalla, J.G.M, Roché, H, del Giglio, A, Ciruelos, E.M, Filho, S. Cabral, Gomez, P, Lluch, A, Llombart, A, Costa, F
Published in European journal of cancer supplements (2009)
Published in European journal of cancer supplements (2009)
Get full text
Journal Article
49P Analysis of HER2-low carcinomas and PAM50 signature in an early-stage breast cancer cohort
Sanchez Bayona, R., Tolosa, P., Alba Bianchi, M., Madariaga Urrutia, A., Teran, S., Rey Cardenas, M., Lema Roso, L., Ruano, Y., Manso, L., Ciruelos, E.M.
Published in Annals of oncology (01.05.2022)
Published in Annals of oncology (01.05.2022)
Get full text
Journal Article
Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial—PEARL
Martin, M., Zielinski, C., Ruiz-Borrego, M., Carrasco, E., Turner, N., Ciruelos, E.M., Muñoz, M., Bermejo, B., Margeli, M., Anton, A., Kahan, Z., Csöszi, T., Casas, M.I., Murillo, L., Morales, S., Alba, E., Gal-Yam, E., Guerrero-Zotano, A., Calvo, L., de la Haba-Rodriguez, J., Ramos, M., Alvarez, I., Garcia-Palomo, A., Huang Bartlett, C., Koehler, M., Caballero, R., Corsaro, M., Huang, X., Garcia-Sáenz, J.A., Chacón, J.I., Swift, C., Thallinger, C., Gil-Gil, M.
Published in Annals of oncology (01.04.2021)
Published in Annals of oncology (01.04.2021)
Get full text
Journal Article
163P Population-adjusted comparison of SOLAR-1 and BOLERO-2: PFS with second-line alpelisib + fulvestrant vs everolimus + exemestane in postmenopausal pts with PIK3CA-mut hormone-receptor positive (HR+) human epidermal growth factor receptor-2 negative (HER2-) advanced breast cancer (ABC)
Ciruelos, E.M., Delea, T., Moynahan, A., Mayer, I., Park, J., Chandiwana, D., Ridolfi, A., Lorenzo, I., Rugo, H.S.
Published in Annals of oncology (01.05.2020)
Published in Annals of oncology (01.05.2020)
Get full text
Journal Article
309P Antineoplastic (ANP) therapies (Tx) after alpelisib (ALP) or placebo (PBO) + fulvestrant (FUL) in patients (Pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–), PIK3CA-mutated (Mut) advanced breast cancer (ABC): An analysis from SOLAR-1
André, F., Rugo, H.S., Juric, D., Rubovsky, G., Yamashita, T., Stemmer, S.M., Lu, Y-S., Miller, M.K., Lorenzo, I., Hu, H., Ciruelos, E.M.
Published in Annals of oncology (01.09.2021)
Published in Annals of oncology (01.09.2021)
Get full text
Journal Article
272TiP HARMONIA SOLTI-2101 / AFT-58: A head-to-head phase III study comparing ribociclib (RIB) and palbociclib (PAL) in patients (pts) with hormone receptor-positive/HER2-negative/HER2-enriched (HR+/HER2-/HER2-E) advanced breast cancer (ABC)
Pascual, T., Stover, D.G., Thuerigen, A., Perou, C.M., Ciruelos, E.M., Casas Fernandez Tejerina, A., Spears, P., Roux, E., Hu, H., Lu, Y-S., Tolaney, S.M., Partridge, A., Villacampa Javierre, G., Ferrero Cafiero, J.M., Carey, L., Prat, A.
Published in Annals of oncology (01.09.2022)
Published in Annals of oncology (01.09.2022)
Get full text
Journal Article
LBA76 Overall survival (OS) results from the phase III TROPiCS-02 study of sacituzumab govitecan (SG) vs treatment of physician's choice (TPC) in patients (pts) with HR+/HER2- metastatic breast cancer (mBC)
Rugo, H.S., Bardia, A., Marmé, F., Cortés, J., Schmid, P., Loirat, D., Tredan, O., Ciruelos, E.M., Dalenc, F., Gomez Pardo, P., Jhaveri, K., Delaney, R.J., Valdez, T., Wang, H., Verret, W., Tolaney, S.M.
Published in Annals of oncology (01.09.2022)
Published in Annals of oncology (01.09.2022)
Get full text
Journal Article
LBA19 Event-free survival (EFS) analysis of neoadjuvant taxane/carboplatin with or without atezolizumab followed by an adjuvant anthracycline regimen in high-risk triple negative breast cancer (TNBC): NeoTRIP Michelangelo randomized study
Gianni, L., Huang, C., Egle, D., Bermejo, B., Zamagni, C., Thill, M., Anton Torres, A., Bianchini, G., Sevillano Fernandez, E., Russo, S., Ciruelos, E.M., Greil, R., Semiglazov, V., Colleoni, M.A., Kelly, C.M., Mariani, G., Del Mastro, L., Spezia, R., Ali, H., Viale, G.
Published in Annals of oncology (01.10.2023)
Published in Annals of oncology (01.10.2023)
Get full text
Journal Article
387MO First results of the SOLTI-1903 HOPE's patient-centric molecular screening program in advanced breast cancer
Pascual, T., Solis, E. Segui, Olivera-Salguero, R., Cejalvo, J.M., Oliveira, M., Ortega, P. Tolosa, Losada, M.J. Vidal, Malumbres, M., Gavilá-Gregori, J., Manich, C. Saura, Simon, S. Pernas, Vila, M. Margeli, Ciruelos, E.M., Galve-Calvo, E., Galván, P., Sanfeliu Torres, E., Olmos, R., Forns, M., Fernandez Tejerina, A. Casas, Prat, A.
Published in Annals of oncology (01.10.2023)
Published in Annals of oncology (01.10.2023)
Get full text
Journal Article
273P A preoperative window-of-opportunity (WOO) study of imlunestrant in ER+, HER2- early breast cancer (EBC): Final analysis from EMBER-2
Neven, P., Stahl, N., Losada, M.J. Vidal, Jimenez, M. Martin, Kaufman, P.A., Harbeck, N., Hunt, K., Carter, S.A., Bidard, F.C., Fasching, P., Aftimos, P.G., Wheatley, D., Hamilton, E.P., Aft, R., Kulkarni, S., Ismail-Khan, R., Karacsonyi, C., Estrem, S.T., Ozbek, U., Ciruelos, E.M.
Published in Annals of oncology (01.10.2023)
Published in Annals of oncology (01.10.2023)
Get full text
Journal Article
112TiP SOLTI-1710 PROMETEO II: Palbociclib in combination with letrozole in patients with hormone receptor-positive (HR+)/HER2-negative residual disease after standard neoadjuvant chemotherapy (NAC)
Ciruelos, E.M., González-Farré, X., Perelló, A., Alba, E., Palacios-Ozores, P., Salvador-Bofil, J., Merino, M., Villagrasa, P., Celiz, P., Pascual, T., Prat, A., Pernas Simon, S.
Published in Annals of oncology (01.05.2020)
Published in Annals of oncology (01.05.2020)
Get full text
Journal Article
91P Gene expression profiling in localised luminal N+ breast cancer: Efficacy and utility of 50 gene expression platform in adjuvant treatment decision making
Tolosa Ortega, P., Sánchez-Torre, A., Carril-Ajuria, L., Herrera, M., Ruiz, Á., Bernal, E., Lema, L., Manso, L., Ciruelos, E.M.
Published in Annals of oncology (01.05.2020)
Published in Annals of oncology (01.05.2020)
Get full text
Journal Article
A phase I dose escalation and expansion trial of the next-generation oral SERD camizestrant in women with ER-positive, HER2-negative advanced breast cancer: SERENA-1 monotherapy results
Hamilton, E., Oliveira, M., Turner, N., García-Corbacho, J., Hernando, C., Ciruelos, E.M., Kabos, P., Ruiz-Borrego, M., Armstrong, A., Patel, M.R., Vaklavas, C., Twelves, C., Boni, V., Incorvati, J., Brier, T., Gibbons, L., Klinowska, T., Lindemann, J.P.O., Morrow, C.J., Sykes, A., Baird, R.D.
Published in Annals of oncology (01.08.2024)
Published in Annals of oncology (01.08.2024)
Get full text
Journal Article